ATE319443T1 - Prävention oder behandlung von brust-, prostata- und/oder gebärmutterhalskrebs mit n,n- dimethylglycin - Google Patents

Prävention oder behandlung von brust-, prostata- und/oder gebärmutterhalskrebs mit n,n- dimethylglycin

Info

Publication number
ATE319443T1
ATE319443T1 AT02764251T AT02764251T ATE319443T1 AT E319443 T1 ATE319443 T1 AT E319443T1 AT 02764251 T AT02764251 T AT 02764251T AT 02764251 T AT02764251 T AT 02764251T AT E319443 T1 ATE319443 T1 AT E319443T1
Authority
AT
Austria
Prior art keywords
breast
prostate
prevention
treatment
cervical cancer
Prior art date
Application number
AT02764251T
Other languages
English (en)
Inventor
Roger V Kendall
Original Assignee
Foodscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foodscience Corp filed Critical Foodscience Corp
Application granted granted Critical
Publication of ATE319443T1 publication Critical patent/ATE319443T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02764251T 2001-04-20 2002-04-19 Prävention oder behandlung von brust-, prostata- und/oder gebärmutterhalskrebs mit n,n- dimethylglycin ATE319443T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83857101A 2001-04-20 2001-04-20

Publications (1)

Publication Number Publication Date
ATE319443T1 true ATE319443T1 (de) 2006-03-15

Family

ID=25277454

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02764251T ATE319443T1 (de) 2001-04-20 2002-04-19 Prävention oder behandlung von brust-, prostata- und/oder gebärmutterhalskrebs mit n,n- dimethylglycin

Country Status (6)

Country Link
EP (1) EP1385497B1 (de)
AT (1) ATE319443T1 (de)
CA (1) CA2444745A1 (de)
DE (1) DE60209757T2 (de)
DK (1) DK1385497T3 (de)
WO (1) WO2002085345A1 (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4385068A (en) * 1980-03-10 1983-05-24 Davinci Laboratories, A Division Of Food Science Corporation N,N-Dimethylglycine and use in immune response
US4994492A (en) * 1989-01-09 1991-02-19 Foodscience Corporation Treatment of melanoma using N,N-dimethylglycine
US5026728A (en) * 1989-10-05 1991-06-25 Foodscience Corporation Treatment of arthritis and inflammation using N,N-dimethylglycine

Also Published As

Publication number Publication date
DE60209757D1 (de) 2006-05-04
EP1385497A4 (de) 2005-06-08
CA2444745A1 (en) 2002-10-31
DE60209757T2 (de) 2006-11-23
WO2002085345A1 (en) 2002-10-31
EP1385497A1 (de) 2004-02-04
DK1385497T3 (da) 2006-07-17
EP1385497B1 (de) 2006-03-08

Similar Documents

Publication Publication Date Title
ATE307608T1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
WO2002005791A3 (en) Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
CZ2000531A3 (en) Method of prevention or therapy of estrogen-dependent diseases and disorders
MY146533A (en) Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
ATE305300T1 (de) Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren
DK1689404T3 (da) Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
NZ512659A (en) Use of growth hormone secretagogues for treatment of physical performance decline
GB0020504D0 (en) Therapeutic method
YU11402A (sh) Nova primena docetaksela za lečenje hepatoma
PT1631275E (pt) Tratamento e prevenção da cicatrização excessiva com 4-hidroxi-tamoxifeno
ATE447426T1 (de) Elektromagnetische stimulation bei patienten mit osteoporose
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE293972T1 (de) Behandlung von chronischen schmerzen
EA200601238A1 (ru) Медикаменты для профилактики и лечения бромидроза и для улучшения запаха тела
DK1077683T3 (da) Antidepressiv behandling
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom
ATE319443T1 (de) Prävention oder behandlung von brust-, prostata- und/oder gebärmutterhalskrebs mit n,n- dimethylglycin
EA200600989A1 (ru) Применение габоксадола для лечения бессонницы
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
TR199801801T2 (xx) Madde k�t�ye kullan�m�n�n tedavisi.
DE60024408D1 (de) Verwendung von trizyklischen antidepressiva zur behandlung von kopfschmerzen
DE69906558D1 (de) Neue therapeutische anwendung von verbindungen mit beta-3-agonistischer aktivität

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties